We are live on ! Find out more
RAPT icon

RAPT Therapeutics

Delisted

RAPT was delisted on the 2nd of March, 2026.

109 hedge funds and large institutions have $847M invested in RAPT Therapeutics in 2021 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 35 increasing their positions, 23 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

372% more capital inflows, than outflows

Capital inflows: $164M | Capital outflows: $34.8M

300% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 10

52% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 23

40% more funds holding

Funds holding: 78 → 109 (+31)

33% more funds holding in top 10

Funds holding in top 10: 9 → 12 (+3)

5.89% more ownership

Funds ownership: 84.85% → 90.74% (+5.9%)

2% less call options, than puts

Call options by funds: $53.3M | Put options by funds: $54.3M

Holders
109
Holders Change
+31
Holders Change %
+39.74%
% of All Funds
1.89%
Holding in Top 10
12
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+33.33%
% of All Funds
0.21%
New
40
Increased
35
Reduced
23
Closed
10
Calls
$53.3​M
Puts
$54.3​M
Net Calls
-⁠$1.02​M
Net Calls Change
-⁠$14.2​M

RAPT Hedge Fund Activity: Q2 2021 in Review

109 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q2 2021, worth a combined $847M — up 81% from $468M a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new RAPT positions and 10 closed out — a net gain of 30 holders — while 35 added to existing stakes and 23 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $23.7M. The largest seller was KPCB XV Associates, cutting an estimated $15.2M.

  • 109 institutional investors held RAPT Therapeutics (RAPT) as of Q2 2021, up from 78 in Q1 2021.
  • Funds reported $847M of RAPT Therapeutics stock for Q2 2021, up 81% quarter-over-quarter.
  • 40 funds opened new RAPT Therapeutics positions in Q2 2021 and 10 closed out, a net change of +30 holders.
  • The largest RAPT Therapeutics buyer in Q2 2021 was T. Rowe Price Associates, an estimated $23.7M added.
  • The largest RAPT Therapeutics seller in Q2 2021 was KPCB XV Associates, an estimated $15.2M sold.

Based on aggregated 13F filings for Q2 2021.